
|Articles|August 15, 2002
- BioPharm International-08-01-2002
- Volume 15
- Issue 8
Throughput Analysis and Debottlenecking of Biomanufacturing Facilities ? A Job for Process Simulators
by Demetri Petrides, Alexandros Koulouris, and Charles Siletti, Intelligen, Inc. Bottlenecks are everywhere, from the freeway overpass during the morning commute to the long lines at the supermarket. But bottlenecks in a manufacturing process are bad for business. Computer models can help you eliminate those conditions or situations that retard your progress. Whether the goal is strategic planning, evaluating alternatives, purchasing equipment, appraising a facility, or optimizing production processes, simulation tools can improve your analysis.
Advertisement
Articles in this issue
about 24 years ago
Guest Editorial: Quality Agreements with Contract Laboratoriesabout 24 years ago
Inside Washington: User Fee Program Seeks to Spur Biotech Developmentabout 24 years ago
Analytical Advances: Mapping Proteins – the 2-D Electrophoresis Issueabout 24 years ago
Your Vested Interests: Gorillas In Our MidstAdvertisement
Related to this article

Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.

This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.

Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.

VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.

As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5


